<DOC>
	<DOC>NCT00723697</DOC>
	<brief_summary>The purpose of this study is to assess the risks of abuse, misuse and adverse events related to high dose buprenorphine. Approximately 1250 patients taking Subutex (Schering-Plough) or its Buprenorphine High Dose (BHD) generic (Arrow Laboratories) will participate in this study. Data will be collected using physician questionnaires and self evaluation patient questionnaires at the first visit and visits at 6 and 12 months.</brief_summary>
	<brief_title>Observational Study of Misuse of High Dose Buprenorphine (SubutexÂ® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)</brief_title>
	<detailed_description>Approximately 380 physicians will participate in this study. Patients will be enrolled in chronological order of consultations.</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Eligible patients will be those already having a prescription for Subutex or its BHD generic, or being proposed a prescription for Subutex or its BHD generic for the first time when consulting the participating physician. The patient must have been informed orally and in writing via the information notice and have signed it. Criteria of noneligibility will be related to the contraindications in the Marketing Authorization (MA) of Subutex or its BHD generic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Subutex</keyword>
</DOC>